4/A: Processa Pharmaceuticals Executive Acquires Shares and Warrants

Sentiment:

SEC Form 4/A


Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, reports acquisition of shares and warrants, both directly and indirectly through the Lin Family Trust.

Summary

  • Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, filed a Form 4/A with the SEC.
  • The report details changes in beneficial ownership of Processa Pharmaceuticals, Inc. [PCSA] securities.
  • On January 29, 2025, Lin acquired warrants exercisable at $0.65 for 43,500 shares of common stock, expiring on January 29, 2030.
  • Lin also acquired warrants exercisable at $0.65 for 21,750 shares of common stock, expiring on January 29, 2030.
  • These warrants are held indirectly through the Lin Family Trust.
  • Lin directly disposed of 29,059 shares of common stock.
  • Lin indirectly owns 43,500 shares of common stock through the Lin Family Trust.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard reporting of insider transactions. The acquisition of warrants could be seen as a positive sign of confidence, but the disposal of shares tempers that view.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.

Key Dates

DateDescription
Feb 4, 2024Date of Lin Family Trust ownership
01/29/2025Date of original filing
01/29/2025Transaction date for warrant acquisition
01/29/2030Expiration date for warrants
02/17/2025Date of earliest transaction
02/18/2025Date of signature

Keywords

Form 4, Beneficial Ownership, Processa Pharmaceuticals, PCSA, Patrick Lin, Warrants, Shares, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.